华东医药子公司DR10624纳入突破性治疗品种名单

Core Viewpoint - East China Pharmaceutical (华东医药) announced that its subsidiary, Zhejiang Daer Biotechnology Co., Ltd., has developed a first-in-class (FIC) long-acting triple-target agonist, DR10624, targeting Fibroblast Growth Factor 21 Receptor (FGF21R), Glucagon Receptor (GCGR), and Glucagon-like Peptide-1 Receptor (GLP-1R), which has been included in the list of breakthrough therapies for the treatment of severe hypertriglyceridemia (sHTG) [1] Group 1 - The long-acting triple-target agonist DR10624 is a novel therapeutic candidate developed by the company [1] - The drug targets three specific receptors: FGF21R, GCGR, and GLP-1R, indicating a multi-faceted approach to treatment [1] - The inclusion of DR10624 in the breakthrough therapy category highlights its potential significance in addressing severe hypertriglyceridemia [1]